CureVac to Pursue mRNA Vaccines Against Flu and Malaria
CureVac AG announced the awarding of two new grants from the Bill & Melinda Gates Foundation. The programs will leverage CureVac’s RNActive® prophylactic vaccine technology to develop mRNA-based vaccines designed to prevent influenza and malaria infection. These vaccines, which are flexible ... more
CureVac and Arcturus Therapeutics announce broad strategic collaboration
CureVac AG and Arcturus Therapeutics Ltd. announced they have entered into a broad strategic collaboration to jointly discover, develop and commercialize novel messenger RNA (mRNA) therapeutics.
Under the agreement, the companies will collaborate to develop up to four molecular therapy prod ... more
CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics
CureVac AG announced the groundbreaking of its industrial-scale, GMP-compliant production facility at its headquarters in Tübingen, Germany. The novel production facility – called GMP IV – will be able to produce approximately 30 million doses of RNA-based therapeutics per year, and is expe ... more